Invivyd Posts Wider Loss In Q3 As Operating Expenses Rise

Invivyd, Inc. (IVVD) reported a wider Q3 net loss of $33.47 million, up from $10.47 million YoY, due to higher operating expenses. Revenue rose 18% to $15.45 million. The company provided updates on its pipeline, including VYD2311 for COVID-19 and VMS063 for measles, and announced leadership changes. Cash reserves totaled $126.40 million.

Original reporting
Published Nov 17, 2026, 9:48 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 9:52 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Invivyd Posts Wider Loss In Q3 As Operating Expenses Rise — source image
Decision brief

The 30-second read

$IVVDBearishMed
01

Why it matters

The quarter’s key decision-relevant inputs are the magnitude of net loss widening and the stated drivers (higher R&D contract costs and higher SG&A), plus the revenue growth from Pemgarda demand and upcoming DECLARATION interim Phase 3 data.

02

Market read

Traders may reprice IVVD on burn-rate concerns from the quarterly loss expansion while monitoring near-term catalysts from upcoming Phase 3 interim data.

03

What to watch

The article highlights Pemgarda demand strength and that LIBERTY Phase 3 met endpoints, which may reduce downside if investors prioritize clinical de-risking over near-term burn.

Relevance 7/10Novelty 7/10Timing: pre-market today (results reported)

Background

Invivyd is a clinical-stage biotech with antibody therapies for viral infectious diseases, including Pemgarda (COVID-19 prevention) and VYD2311 (COVID-19).

Company-level read

Ticker impact

$IVVDBearishMedium confidence
Context

Invivyd reported Q3 net loss widening to $33.47M as R&D and SG&A rose, alongside revenue up 18% on Pemgarda demand.

Expected impact

Likely near-term downside or volatility as investors weigh cost inflation against incremental revenue and trial catalysts.

Evidence & confidence

The article discloses a fresh quarterly loss expansion with specific expense drivers, which typically dominates biotech sentiment, while pipeline updates provide longer-dated support.

Market effects

Reinforces the biotech tape focus on burn rate and operating expense growth, even when product revenue improves.

No clear regional spillover beyond US small-cap biotech sentiment.

Limited, as the catalysts are company-specific clinical and commercial updates.

Counterpoint

Expense growth may reflect deliberate scaling ahead of accelerated-approval efforts, so the loss widening could be a temporary investment phase.

Key entities

  • Invivyd, Inc.

    Reported Q3 2026 results with wider net loss, higher operating expenses, and revenue growth tied to Pemgarda demand.

  • VYD2311 (ibramvibart)

    Phase 3 LIBERTY met endpoints; DECLARATION interim data expected imminently; FLINTLOCK began in October.

  • Pemgarda (pemivibart)

    Revenue increased 18% in Q3, attributed to increased demand.

Related articles

$IVVDHigh

Invivyd Reports Third Quarter 2026 Financial Results and Recent

Invivyd, Inc. (IVVD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights • DECLARATION Phase 3 clinical trial data on VYD2311 (ibramvibart) to be available imminently, per the Accelerated Approval analysis and regulatory submission plan previously communic

$IVVDMedAI 8/10

Invivyd presents preclinical data on measles antibody candidate

Invivyd (NASDAQ:IVVD) presented preclinical data for its measles antibody candidate VMS063 at IDWeek 2026, showing antiviral activity against measles virus variants. The company plans to scale up manufacturing for clinical development in 2027. There are currently no FDA-approved treatments for measles, with U.S. cases nearly double in 2026 compared to 2025, according to Invivyd.

$IVVDLow

Invivyd, Inc. (IVVD) Unveils Preclinical Data for Measles mAb VMS063

Invivyd, Inc. (IVVD) presented preclinical data for VMS063, a novel monoclonal antibody for measles, showing in vitro activity against contemporary virus variants. The company is scaling up production for clinical development in 2027. There are currently no FDA-approved treatments for measles, and the U.S. is experiencing a surge in cases.

$IVVDLowAI 8/10

More than 9 million U.S. children are estimated to lack measles protection. Lab tests found an antibody could fight measles.

Invivyd (Nasdaq: IVVD) presented preclinical data for VMS063, a monoclonal antibody candidate for measles treatment and prevention. VMS063 showed potent in vitro activity against measles virus variants. Invivyd plans to scale up production for clinical development in 2027. The U.S. is experiencing a record number of measles cases in 2026, with over 9 million children unprotected.

$IVVDMedAI 8/10

Invivyd launches phase 2 trial of VYD2311 for long COVID

Invivyd (NASDAQ:IVVD) initiated a Phase 2 trial of VYD2311 for Long COVID and Post-Vaccination Syndrome. The trial will enroll 130 participants and assess safety, tolerability, and efficacy over 90 days. VYD2311 has shown in vitro potency against SARS-CoV-2 variants. Initial data is expected in mid-2027. The trial is part of Invivyd’s broader REVOLUTION clinical program.